Treatment of multiple sclerosis (MS)

a technology for multiple sclerosis and treatment, applied in the field of treatment of multiple sclerosis, to achieve the effect of significant efficacy and favorable safety profil

Inactive Publication Date: 2013-05-02
ALCAFLEU MANAGEMENT +1
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016]The present invention relates to a method for the treatment of multiple sclerosis (MS) with Campath-1H, with significant efficacy and a favourable safety profile which offers an acceptable benefit / risk ratio. It also relates to the use of Campath-1H for the production of a medicament for the treatment of multiple sclerosis (MS).

Problems solved by technology

In summary, administration of Campath-1H at to patients with MS has shown efficacy in treating the disease, but such administration has also been associated with adverse events, which may include infectious and auto-immune complications.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of multiple sclerosis (MS)
  • Treatment of multiple sclerosis (MS)
  • Treatment of multiple sclerosis (MS)

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0080]An open, rater blinded, randomized, multicenter trial in treatment naïve patients with early active relapsing-remitting multiple sclerosis is performed. The first treatment cycle of Campath-1H consists of 5 daily doses of 12 mg at Month 0. The second (fixed) treatment cycle consists of 3 daily doses of 12 mg at Month 12. Subsequently, re-treatment of patients with 3 daily doses of 12 mg Campath-1H only occurs once evidence of renewed MS activity is observed in the respective patient. Thus, the third and subsequent cycles are administered only if the patients have evidence of renewed MS activity, in this example defined as at least 1 documented clinical relapse or presentation of at least 3 new MRI lesions (total) compared to the MRI following the prior Campath-1H treatment (i.e. “re-treatment as needed” regimen). If these criteria are fulfilled, the patient may be immediately retreated.

[0081]If a Campath-1H patient has received steroids for symptomatic treatment of a relapse w...

example 2

[0083]MS patients are treated as set forth above, except that the first treatment cycle of Campath-1H consists of 2 daily doses of 10 mg at Month 0 and the second treatment cycle consists of two daily doses of 10 mg at Month 12. Subsequently re-treatment of patients with 2 daily doses of 10 mg Campath-1H only occurs once evidence of renewed MS activity is observed as described in Example 1 (“re-treatment as needed”).

example 3

[0084]MS patients are treated using the same treatment regimens as outlined in Examples 1 or 2, except that the second and subsequent re-treatments are on a re-treatment as needed basis provided that at least 6 months have passed since the prior Campath-1H treatment cycle (dosing period).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to view more

Abstract

A method for treatment of multiple sclerosis (MS) with Campath-1H with significant efficacy and a favourable safety profile is described, which offers an acceptable benefit / risk ratio. Especially described is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first treatment cycle followed by at least one further treatment cycle of Campath-1H (alemtuzumab), in which each treatment cycle comprises 1-5 daily doses which are applied on consecutive days, wherein the daily dose is >0 and ≦12 mg, and wherein each treatment cycle is separated from the next cycle by at least 1-24 months. Also described are treatment regimens comprising the administration of less than 12 mg / day of Campath-1H for a period of 1-5 consecutive days.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 11 / 900,211, filed Sep. 10, 2007, now pending, which claims the benefit of U.S. Provisional Application No. 60 / 844,251, filed Sep. 13, 2006, now expired. The entire disclosures of the above-identified priority applications are incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that affects as many as 2.5 million people worldwide. The pathogenesis of MS remains poorly understood but is believed to arise from the interplay of polygenic inherited susceptibility and an unidentified environmental agent(s). It is approximately twice as common among women as men. Worldwide, its prevalence varies geographically and, within the same country, between different racial groups. Prevalence is highest amongst Caucasians in countries distant from the Equator, for instance Scotland and Scandinavia. Peak ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395
CPCA61K2039/505A61K39/3955C07K16/2893A61K2039/545
Inventor MARGOLIN, DAVID H.SACHSE, ANDREAS
Owner ALCAFLEU MANAGEMENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap